Skip to main content

Table 1 Neurological characteristics of the patients on study entry (overall and by genotype, AT vs. AA)

From: Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease

  Delayed-start group Early-start group
Total Total AT genotype AA genotype
Number of patients 19 21 5 14
Age at study entry (years) 60 [54–64] 61 [54–66] 62 [61–62] 61 [53–66]
Gender (F/M) 6/13 9/12 3/2 6/10
Time since diagnosis (years) 2 [1–3] 2 [1–3] 2 [1–3] 2 [1–3]
Hoehn and Yahr stage (range, 1–5) 2 [1.5-2] 2 [1.5-2] 2 [1.5-2] 2 [1.4-2]
Daily L-dopa dose equivalent (mg) 300 [162–510] 300 [150–532] 300 [150–532] 300 [150–532]
Patients on L-dopa (n) 9 10 3 7
Patients on dopaminergic agonists (n, mean daily L-dopa equivalent in mg) 18 (243) 18 (220) 4 (225) 13 (250)
Patients on L-dopa and agonists (n) 7 7 2 5
Patients on rasagiline (n) 3 3 1 2
Mini Mental Scale Examination score 29 [28–30] 28 [26–30] 28 [27–29] 28 [26–30]
Mattis Dementia Rating Scale score 139 [138–141] 139 [134–143] 139 [138–140] 139 [133–143]
Epworth Sleepiness Scale score 9 [7–13] 9 [5–13] 8 [6–10] 9 [5–13]
Montgomery Asberg Depression Rating Scale 3 [2–4] 4 [2–5] 3 [2–5] 4 [2–5]
Cognition and behavior: MDS-UPDRS part I score 6 [5–8] 6 [4.7-9] 5 [4–7] 6 [4.7-9]
  1. There were no significant intergroup differences. The dopaminergic drug regimens did not change over the course of the study. Quantitative variables are quoted as the median [interquartile range]. MDS means Movement Disorders Society.